Biotech Business - September 4, 2026
Modus Therapeutics raises SEK 7.6 million ahead of key clinical milestone
The company has completed a directed share issue as it approaches proof-of-concept data from its Phase IIa study in chronic kidney disease with anemia, expected around the turn of the year.
Financing - September 2, 2026
Readily Diagnostics wins Gates Foundation grant for affordable STI test
Uppsala-based Readily Diagnostics has received a grant of approximately USD 970,000 (about SEK 9 million) from the Gates Foundation to develop a low-cost point-of-care test for chlamydia, gonorrhea and trichomoniasis, aimed at low-resource settings.
Biotech Business - August 26, 2026
Gubra receives USD 50 million milestone payment from AbbVie
The Danish biotech has triggered a milestone payment from AbbVie after the pharma giant advanced ABBV-295, a long-acting amylin analog for chronic weight management, into a Phase 2 clinical trial – the latest payout under the pair's 2025 obesity licensing deal.
Financing - August 20, 2026
Pixelgen Technologies raises USD 15.5 million
Pixelgen Technologies has closed an oversubscribed USD 15.5 million Series B financing to accelerate global commercialization of its Proxiome Kit and expand the company’s presence in key markets.
Europe - July 23, 2026
Fresenius establishes venture fund of more than EUR 200 million
With an intended investment volume of more than EUR 200 million over the next 5 years, Fresenius Ventures targets growth fields adjacent to Fresenius’ existing strategic platforms (Bio)Pharma, MedTech, and Care Provision.
Financing - July 1, 2026
Cereno Scientific carries out directed share Issue of SEK 60 million
The Directed Issue has been directed to existing shareholders and a new investor and is carried out at a subscription price corresponding to a premium of approximately 4.08 percent compared with the latest closing price.
